GPS Wealth Strategies Group’s Arbutus Biopharma ABUS Stock Holding History

GPS Wealth Strategies Group’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-700	Closed	-$2.12K	–	1243
2023 Q1	$2.12K	Buy	+700	New	+$1.98K	﹤0.01%	1115
2022 Q4	–	Sell	-700	Closed	-$1K	–	125
2022 Q3	$1K	Hold	700	–	–	﹤0.01%	1061
2022 Q2	$2K	Sell	700 -1,165	-62%	-$2.98K	﹤0.01%	1003
2022 Q1	$6K	Sell	1,865 -500	-21%	-$1.53K	﹤0.01%	810
2021 Q4	$9K	Hold	2,365	–	–	﹤0.01%	745
2021 Q3	$10K	Hold	2,365	–	–	﹤0.01%	706
2021 Q2	$7K	Sell	2,365 -1,000	-30%	-$3.1K	﹤0.01%	796
2021 Q1	$11K	Buy	+3,365	New	+$13K	﹤0.01%	650

Other funds holding ABUS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TSC

Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

WCM

Whitefort Capital Management New York $406M AUM 84.26% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

GPS Wealth Strategies Group's ABUS Position: Q2 2023 in Review

GPS Wealth Strategies Group sold out of Arbutus Biopharma (ABUS) in Q2 2023, closing a stake of 700 shares — an estimated $2.12K sold.

GPS Wealth Strategies Group first reported a position in ABUS in Q1 2021 and held it in 8 quarters. The position peaked at $11K in Q1 2021. 111 funds tracked by Wall St. Rank hold ABUS as of Q2 2023.

GPS Wealth Strategies Group reported no remaining Arbutus Biopharma position as of Q2 2023 after selling out during the quarter.
GPS Wealth Strategies Group sold 700 Arbutus Biopharma shares in Q2 2023, an estimated $2.12K.
GPS Wealth Strategies Group first reported a position in Arbutus Biopharma in Q1 2021 and held it in 8 quarters.
GPS Wealth Strategies Group's Arbutus Biopharma position peaked at $11K in Q1 2021.
111 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2023.

Based on GPS Wealth Strategies Group's 13F filing for Q2 2023, filed 17 Jul 2023.